Ultra-High-Dose Lanreotide Treatment in Patients with Metastatic Neuroendocrine Gastroenteropancreatic Tumors

Publisher： Karger

E-ISSN： 1421-9867|60|5|469-476

ISSN： 0012-2823

Source： Digestion, Vol.60, Iss.5, 1999-08, pp. : 469-476

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical Usefulness of Somatostatin Receptor Scintigraphy in Japanese Patients with Gastroenteropancreatic Neuroendocrine Tumors

By  

Digestion, Vol. 96, Iss. 1, 2017-06 ,pp. : 13-20

Karger

Access to resources Recommend Favorite

Biological and Molecular Aspects of Gastroenteropancreatic Neuroendocrine Tumors

By  

Digestion, Vol. 62, Iss. 1, 2000-07 ,pp. : 19-26

Karger

Access to resources Recommend Favorite

Alkaline Phosphatase Predicts Survival in Patients with Metastatic Neuroendocrine Tumors

By Clancy Thomas   Sengupta Tanya   Paulus Jessica   Ahmed Fawzia   Duh Mei-Sheng   Kulke Matthew  

Digestive Diseases and Sciences, Vol. 51, Iss. 5, 2006-05 ,pp. : 877-884

Springer Publishing Company

Access to resources Recommend Favorite

The Role of Octreotide in the Treatment of Gastroenteropancreatic Endocrine Tumors

By  

Digestion, Vol. 60, Iss. 2, 1999-04 ,pp. : 9-14

Karger

Access to resources Recommend Favorite

Treatment of neuroendocrine tumors with somatostatin analogs

By Janson Eva  

Pituitary, Vol. 9, Iss. 3, 2006-09 ,pp. : 249-256

Springer Publishing Company

Access to resources Recommend Favorite